Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).
Roberto Debbag, María L Avila-Agüero, Angela Gentile, Jaime Torres, Carlos Torres, Liliana Vazquez, Claudia Beltran, José Brea-Del Castillo, Ron Dagan
{"title":"Post-pandemic impact on the epidemiology of invasive pneumococcal disease: consensus statement from the Latin American Society of Pediatric Infectious Diseases (SLIPE).","authors":"Roberto Debbag, María L Avila-Agüero, Angela Gentile, Jaime Torres, Carlos Torres, Liliana Vazquez, Claudia Beltran, José Brea-Del Castillo, Ron Dagan","doi":"10.1080/14760584.2026.2689604","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The Latin American Society of Pediatric Infectious Diseases (SLIPE) convened a multidisciplinary expert panel to assess the post-pandemic epidemiology of invasive pneumococcal disease (IPD) in Latin America and the Caribbean. The COVID-19 pandemic initially reduced IPD incidence due to non-pharmaceutical interventions, but subsequent relaxation of restrictions, coupled with immunization gaps, led to a resurgence of pneumococcal infections. The consensus statement reviews literature and regional surveillance data to analyze how disrupted vaccination programs, socioeconomic inequities, and weakened healthcare systems amplified the regional vulnerability to vaccine-preventable diseases.</p><p><strong>Areas covered: </strong>This document addresses epidemiologic changes in IPD following the pandemic, the interplay between respiratory viral infections and pneumococcal disease, trends in pneumococcal conjugate vaccine (PCV) coverage and related barriers, and the emergence of non-vaccine serotypes causing IPD.</p><p><strong>Expert opinion: </strong>Sustaining herd protection in the region requires strengthening vaccination infrastructure, restoring confidence through effective communication, and ensuring the completion of booster doses in the second year of life. Despite limited serotype data, countries should prioritize the timely adoption of higher-valency PCVs in feasible schedules to mitigate the growing burden of pneumococcal disease and prevent further setbacks in child health.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2689604"},"PeriodicalIF":5.6000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2026.2689604","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The Latin American Society of Pediatric Infectious Diseases (SLIPE) convened a multidisciplinary expert panel to assess the post-pandemic epidemiology of invasive pneumococcal disease (IPD) in Latin America and the Caribbean. The COVID-19 pandemic initially reduced IPD incidence due to non-pharmaceutical interventions, but subsequent relaxation of restrictions, coupled with immunization gaps, led to a resurgence of pneumococcal infections. The consensus statement reviews literature and regional surveillance data to analyze how disrupted vaccination programs, socioeconomic inequities, and weakened healthcare systems amplified the regional vulnerability to vaccine-preventable diseases.
Areas covered: This document addresses epidemiologic changes in IPD following the pandemic, the interplay between respiratory viral infections and pneumococcal disease, trends in pneumococcal conjugate vaccine (PCV) coverage and related barriers, and the emergence of non-vaccine serotypes causing IPD.
Expert opinion: Sustaining herd protection in the region requires strengthening vaccination infrastructure, restoring confidence through effective communication, and ensuring the completion of booster doses in the second year of life. Despite limited serotype data, countries should prioritize the timely adoption of higher-valency PCVs in feasible schedules to mitigate the growing burden of pneumococcal disease and prevent further setbacks in child health.
期刊介绍:
Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.